Sigmoid Pharma is headquartered at the “Invent Centre” advanced technologies incubator on the campus of Dublin City University in Ireland’s capital city.

The company has developed two proprietary oral pharmaceutical formulation technologies known as LEDDS® (liquid/emulsion drug delivery system) and SmPill® (single-multiple pill) which it employs in developing its own products as well as those of partners.

The company, formerly known as Sigmoid Biotechnologies, was founded in 2003 to exploit know-how in the areas of oral drug formulation and the science of the very small. In 2007, the company changed its name to Sigmoid Pharma to reflect its decision to develop a pipeline of proprietary pharmaceutical products.

Sigmoid has approximately 20 highly trained employees operating in close collaboration with a network of professional service-providers internationally to underpin state-of-the-art development and manufacturing capabilities. Sigmoid has its own manufacturing facility, licensed by the Irish Medicines Board to release materials for clinical use.

To maintain its leading position in the field of oral drug delivery, the company also conducts research in collaboration with academic institutions internationally.